# SU011248 In The Treatment Of Patients With Bevacizumab (Avastin)-Refractory Metastatic Renal Cell Carcinoma

> **NCT00089648** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 61 (actual)

## Conditions studied

- Carcinoma, Renal Cell

## Interventions

- **DRUG:** Sunitinib

## Key facts

- **NCT ID:** NCT00089648
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** 2007-01
- **Final completion:** 2008-03
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2010-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00089648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00089648, "SU011248 In The Treatment Of Patients With Bevacizumab (Avastin)-Refractory Metastatic Renal Cell Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00089648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*